A Phase 3 interventional study of Romozosumab and Teriparatide in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 50 sites in 11 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 4th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2013.
This study's enrollment of 436 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 9th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 17th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
Drug: Romozosumab
Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
Drug: Teriparatide
Administered by subcutaneous injection once a month.
Also known as: AMG 785
Administered by subcutaneous injection once a day.
Also known as: Forteo, Forsteo
Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA). Percent change from baseline through month 12 is the average of the treatment effect at months 6 and 12.
Time frame: Baseline, month 6 and month 12
Percent Change From Baseline in Total Hip BMD at Month 6
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 6
Percent Change From Baseline in Total Hip BMD at Month 12
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 12
Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6
Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.
Time frame: Baseline and month 6
Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12
Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.
Time frame: Baseline and month 12
Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6
Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.
Time frame: Baseline and month 6
Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12
Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.
Time frame: Baseline and month 12
Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6
Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.
Time frame: Baseline and month 6
Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12
Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.
Time frame: Baseline and month 12
Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6
Total hip integral BMC was measured using quantitative computed tomography (QCT).
Time frame: Baseline and month 6
Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12
Total hip integral BMC was measured using quantitative computed tomography (QCT).
Time frame: Baseline and month 12
Percent Change From Baseline in Femoral Neck BMD at Month 6
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 6
Percent Change From Baseline in Femoral Neck BMD at Month 12
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 12
Percent Change From Baseline in Lumbar Spine BMD at Month 6
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 6
Percent Change From Baseline in Lumbar Spine BMD at Month 12
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 12
The study was conducted at 46 sites in North America, Latin America, and Europe. Participants were enrolled from 31 January 2013 to 29 April 2014.
| Milestone | Teriparatide | Romosozumab |
|---|---|---|
| Started | 218 | 218 |
| Received treatment | 214 | 218 |
| Completed | 200 | 198 |
| Not completed | 18 | 20 |
| Withdrew: Withdrawal by subject | 15 | 15 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Decision by sponsor | 0 | 1 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA). Percent change from baseline through month 12 is the average of the treatment effect at months 6 and 12.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD) | -0.6 ± 0.2 | 2.6 ± 0.2 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Total Hip BMD at Month 6 | -0.8 ± 0.2 | 2.3 ± 0.2 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Total Hip BMD at Month 12 | -0.5 ± 0.2 | 2.9 ± 0.2 |
Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6 | -2.7 ± 0.2 | 0.7 ± 0.2 |
Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12 | -3.6 ± 0.3 | 1.1 ± 0.3 |
Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6 | -0.8 ± 0.2 | 2.3 ± 0.2 |
Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12 | -0.2 ± 0.2 | 3.4 ± 0.2 |
Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6 | -1.0 ± 0.2 | 2.1 ± 0.2 |
Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12 | -0.7 ± 0.4 | 2.5 ± 0.4 |
Total hip integral BMC was measured using quantitative computed tomography (QCT).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6 | -0.7 ± 0.2 | 2.4 ± 0.2 |
Total hip integral BMC was measured using quantitative computed tomography (QCT).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12 | 0.0 ± 0.2 | 3.6 ± 0.2 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD at Month 6 | -1.1 ± 0.3 | 2.1 ± 0.3 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD at Month 12 | -0.2 ± 0.3 | 3.2 ± 0.3 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD at Month 6 | 3.5 ± 0.3 | 7.2 ± 0.3 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Teriparatide | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD at Month 12 | 5.4 ± 0.4 | 9.8 ± 0.4 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teriparatide | — | 23/214 (10.7%) | 76/214 (35.5%) |
| Romosozumab | — | 17/218 (7.8%) | 79/218 (36.2%) |
| Event | Teriparatide | Romosozumab |
|---|---|---|
| Abdominal painGastrointestinal disorders | 2/214 | 0/218 |
| PneumoniaInfections and infestations | 2/214 | 1/218 |
| Atrial fibrillationCardiac disorders | 0/214 | 2/218 |
| Arrhythmia supraventricularCardiac disorders | 1/214 | 0/218 |
| Sinus bradycardiaCardiac disorders | 1/214 | 0/218 |
| VertigoEar and labyrinth disorders | 1/214 | 0/218 |
| DiarrhoeaGastrointestinal disorders | 1/214 | 0/218 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/214 | 0/218 |
| Large intestinal ulcerGastrointestinal disorders | 1/214 | 0/218 |
| Small intestinal obstructionGastrointestinal disorders | 1/214 | 0/218 |
| Event | Teriparatide | Romosozumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 22/214 | 28/218 |
| HypercalcaemiaMetabolism and nutrition disorders | 22/214 | 2/218 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/214 | 22/218 |
| Back painMusculoskeletal and connective tissue disorders | 12/214 | 19/218 |
| HeadacheNervous system disorders | 9/214 | 14/218 |
| FallInjury, poisoning and procedural complications | 5/214 | 12/218 |
| Upper respiratory tract infectionInfections and infestations | 9/214 | 11/218 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 5/214 | 11/218 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/214 | 11/218 |
| Age, Continuous(years) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| Mean | 71.2 ± 7.7 | 71.8 ± 7.4 | 71.5 ± 7.5 |
| Age, Customized(Participants) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| < 65 years | 48 | 50 | 98 |
| ≥ 65 to < 75 years | 96 | 83 | 179 |
| ≥ 75 years | 74 | 85 | 159 |
| Sex: Female, Male(Participants) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| Female | 218 | 218 | 436 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| White | 196 | 191 | 387 |
| Other | 18 | 23 | 41 |
| American Indian or Alaska Native | 1 | 4 | 5 |
| Asian | 2 | 0 | 2 |
| Multiple | 1 | 0 | 1 |
| Prior Fracture(Participants) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| Yes | 217 | 218 | 435 |
| No | 1 | 0 | 1 |
| Lumbar Spine BMD T-score(T-score) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| Mean | -2.87 ± 1.04 | -2.83 ± 1.10 | -2.85 ± 1.07 |
| Total Hip BMD T-score(T-score) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| Mean | -2.21 ± 0.72 | -2.27 ± 0.75 | -2.24 ± 0.74 |
| Femoral Neck BMD T-score(T-score) | Teriparatide | Romosozumab | Total |
|---|---|---|---|
| Mean | -2.43 ± 0.66 | -2.49 ± 0.67 | -2.46 ± 0.66 |
1 further baseline measures are reported on the registry.
Ran from Jan 2013 to primary completion in May 2015, 27 months.
Results were first posted in Nov 2018, 3 years 5 months after primary completion. A results delay was requested in Dec 2015.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 27 months is above that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →